The World's Greatest Investing Community
Results 21 - 30 of 1467 : Previous 1 2 3 4 5 6 7 8 9 Next
Don't Read Too Much Into This Partnership
Sometimes a deal is just a deal, not a sign of M&A to come.
This Biotech's Obese To-Do List Is Done
Arena resubmits lorcaserin for FDA approval.
You Know What's Overrated? Retirement.
Lessons learned from a thought-provoking book.
The First Thing You Should Do in 2012
You still have to start saving for retirement.
Working Through the Obese To-Do List in 2011
Arena ends the year on an upswing.
What to Look For With Seattle Genetics in 2012
The launch of its new drug Adcetris will be key.
Abbott Labs: Dividend Dynamo or the Next Blowup?
What the numbers tell us.
How I'll hold myself accountable for all of my screens.
Biotech Post-Holiday Regifting
Sometimes it's better to not have received in the first place.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK